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PP-005 An analysis on the rational application of
antibiotics in the department of gastrointestinal
surgery
H.S. Ye1, C.R. Zhang1 *, L. Tang1, W. Yang1. 1Huang Pu
Hospital of the First Afﬁliated Hospital, Sun Yat-sen
University, China
Objective: To realize the circumstances of the antibiotic
application during perioperational period, the rational
application of antimicrobial agents was evaluated in the
department of gastrointestinal Surgery in a hospital.
Methods: Retrospective study for 210 patients in the
department of gastrointestinal Surgery form Jan. 2007 to
Dec. 2008 was carried out at random.
Results: The antibacterial agents were used in all patients
during perioperation; The antibacterial agents used most
frequently were Metronidazole and Cephalosporins, The
combined use cases were 90.5%. The average period of
treatment was 7 days. The incidence of surgical site
infection was 8.6%. Only 55.6% patients’ samples were
examined and drug susceptibility test were detected.
Conclusion: The irrational applications of prophylactic
antibiotitcs during the perioperative period are serious,
such as the average time of using antibiotics was too long,
unreasonable frequently sort changing and low rate for
samples detecting.
PP-006 Resistance to phenoxymethylpenicillin
(penicillin V) in bacteria causing paediatric
infections in European countries
S. Yazdankhah1 *. 1Norwegian Medicines Agency, Norway
In paediatrics, penicillin V has been primarily used
for the treatment of ear, nose and throat infections,
lower respiratory tract infections, skin and soft tissue
infections. Penicillin V is less potent than benzylpenicillin
(penicillin G). Resistance mechanisms in bacteria towards
penicillin V and G are similar. Three major groups of
bacteria involved as causative agents in paediatric diseases
are: Streptococcus pyogenes, Streptococcus pneumoniae
and Haemophilus inﬂuenzae. According to the published
articles, current resistance situation for penicillin (V and G)
in Europe for above-mentioned bacteria can be summarised
as follows:
• S. pyogenes: Penicillin-resistant S. pyogenes has never
been observed to date.
• S. pneumoniae: Penicillin non-susceptibly shows a
heterogeneous picture in Europe:
Norway, Sweden, UK, the Netherlands and Germany had
low levels of non-susceptibility (<5%),
Moderate levels of non-susceptible strains in Belgium,
Finland, and Ireland,
High levels of penicillin non-susceptible S. pneumoniae
above 25% were mainly reported from Southern and
Eastern Europe: Cyprus, France, Poland, Romania and
Turkey.
The prevalence of non-susceptibility to penicillin seems
to be declining (with more than 10%) in the high-
prevalence area, e.g., France and Spain.
• H. inﬂuenzae: An increasing isolation rate of resistant
strains has been reported since the emergence of
beta-lactamase producing H. inﬂenzae in 1974. There
is insufﬁcient evidence that H. inﬂuenzae is a good
target for therapy with the penicillin V. The wild type
distributions of MIC values given in the EUCAST database
suggest that there may be only one resistant population
of H. inﬂuenzae. Thus, it can be speculated that this
pathogen may harbour inherent resistance.
Conclusions: Penicillin V is still drug of choice for treatment
of S. pyogenes, but its activity has been reduced signiﬁcantly
for S. pneumoniae and H. inﬂuenzae in the last three
decades.
PP-007 Difference in epidemiology and antibiotic
susceptibility of methicillin resistant and
methicillin susceptible Staphylococcus aureus
isolates
H. Saderi1 *, P. Owlia1, M.R. Jalali Nadoushan2. 1Department
of Microbiology, Faculty of Medicine, Shahed University,
2Department of Pathology, Faculty of Medicine, Shahed
University, Iran
Objectives: Antimicrobial resistance of Staphylococcus
aureus especially methicillin resistant S. aureus (MRSA)
continues to be a problem for clinicians worldwide. Although
difference in epidemiology and antibiotic susceptibility of
methicillin resistant S. aureus and methicillin susceptible
S. aureus (MSSA) isolates has been proposed by
investigators, few data have been reported to now.
Methods: Disk diffusion method was used for determination
of in-vitro susceptibility of S. aureus isolates to 15
antibiotics. Susceptibility pattern of 192 non-duplicates
S. aureus isolated from clinical specimens in four university
hospital in Tehran, from November 2007 to August 2008,
were compared. In addition, distribution of MRSA and MSSA
isolates were investigated in different specimens, on various
wards, and in different age groups.
Results: MRSA isolates were constituted 49% of all isolates.
While only 1.7% of the MSSA isolates were multidrug
resistant, all of MRSA were shown resistance to at least
ﬁve antibiotics. Majority of isolates from patients 65 years
old were MRSA and prevalence of methicillin resistance
was highest among S. aureus isolated from respiratory
specimens. Also, MRSA appeared to be more prevalent in
intensive care units and operation wards than in other
departments.
Conclusion: This study has shown a relationship between
methicillin resistance and resistance to other antibiotics
in S. aureus isolates. Also, considerable differences were
observed in epidemiology of MRSA and MSSA isolates.
PP-008 Surveillance of antimicrobial resistance in
infectious diseases hospitals in Romania
L.C. Gavriliu1,2 *, G.A. Popescu1,2, C. Popescu1,2,
E. Nicoara3, E. Miftode4, S. Rugina5, E. Benea1,2,
C. Gubavu1, S. Gliga1. 1“Prof Dr. Matei Bals” National
Institute of Infectious Diseases, Bucharest, Romania,
2“Carol Davila” University of Medicine, Bucharest,
Romania, 3“Victor Babes” Infectious Diseases Hospital,
Timisoara, Romania, 4“St. Paraschieva” Infectious Diseases
Hospital, Iasi, Romania, 5Infectious Diseases Hospital,
Constanta, Romania
Background: Antimicrobial resistance data could improve
the quality of local treatment guidelines in various
infectious diseases. We started a surveillance study to
evaluate the level of resistance in four infectious diseases
hospitals from Romania.
Methods: A four-center (Infectious Diseases Hospitals from
Iasi, Constanta, Timisoara and National Institute Matei Bals)
retrospective study of bacterial antimicrobial susceptibility
was performed over a twelve month period (July 2008
June 2009).
Results: We analysed 3995 bacterial isolates, duplicates and
bacteria isolated from feces being excluded. More than half
of the tests were performed in the “Matei Bals” National
Institute (52.26%). 56.32% of the results were obtained using
the disk diffusion method.
High levels of resistance were noted for Streptococcus
pneumoniae, with diminished susceptibility for penicillin
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at 28.41% and 46.32% resistance to macrolides; 42.33%
of isolates were MRSA; Enterococcus faecalis had a
level of 14.49% resistance to ampicillin; Pseudomonas
spp. showed a 47.46% level of ﬂuoroquinolones-resistance
and a 36.11% level of carbapenem-resistance (imipenem
and/or meropenem); 24.81% of Enterobacteriaceae were
ﬂuoroquinolone-resistant and 23.11% were resistant to third
generation cephalosporins; 73.07% of Acinetobacter isolates
were carbapem-resistant; Escherichia coli had the following
spectrum of resistance: 24.21% ﬂuorquinolone-resistance
and 15.3% third generation cephalosporin-resistance.
Conclusions: The resistance levels are quite high, in
accordance with the EARSS reported Romanian data, and in
some situations even higher. Limitations of this study could
be due to technical problems or statistical inaccuracy. A
more thorough and clear research of susceptibility testing is
mandatory and more data is necessary in order to elaborate
valid treatment guidelines.
PP-009 Efﬁcacy of ceftazidime plus amikacin as an
initial empirical therapy for adult patients with
febrile neutropenia
A. Alwan1 *, A. Alshami1, M. Alani2. 1The National Center
of Hematology, Almustansiriya University, 2Medical
Microbiology Department, Baghdad University College of
Medicine, Iraq
Background: Empirical broad-spectrum antibiotic therapy
remains the cornerstone of treatment for febrile
neutropenic patients. The aim of this study was to evaluate
the efﬁcacy of ceftazidime plus Amikacin as empirical
therapy in patients with febrile neutropenia.
Methods: Non-randomized prospective study conducted in
the national center of hematology from May 2009 to
March 2010. Adult patients treated for acute leukemias and
presented with febrile neutropenia included in this study.
Patients received ceftazidime 2g twice daily plus amikacin
at a dose of 15mg/kg twice daily (maximum 20mg/kg).
If fever persisted, a second-line therapy with meropenem
was administered. Teicoplanin was given for Gram-positive
isolates or for unremitting fever after 48 hours.
Table 1. Clinical characteristics of patients and febrile episodes
Patients Febrile episodes
Total no. 54 89
Median age, years (range) 24 (15 72)
Gender (male/female) 51/38
Cause of neutropenia, no. (%)
Acute lymphoblastic leukemia 22 (40.7) 37 (41.5)
Acute myeloid leukemia 32 (59.2) 52 (58.4)
G-CSF added, no. (%)
Yes 0(92.5)
No 4 (7.5)
Prophylaxis antibiotic, no. (%)
Yes 51 (94.4)
No 3 (5.6)
Median ANC at presentation, ×109 (range) 0.10(0.00.- 0.50)
Episode classiﬁcation, no. (%)
Microbiologically documented 19 (21.3)
Clinically documented 27 (30.3)
Fever of unknown origin 43 (48.3)
G-CSF: granulocyte-colony stimulating factor; ANC: absolute neutrophil count.
Results: 89 episodes of fever and neutropenia were
evaluated in 54 patients. 19 (21.3%) of episodes were
documented microbiologically, while 27 (30.3%) of episodes
were clinically documented, and 43 (48.3%) were fever
of unknown origin. 35 (39.3%) of total episodes showed
response to ceftazidime plus amikacin, while 54 (60.6%)
showed no response and required treatment modiﬁcation.
The predominant pathogens isolated in this study were
Gram-negative organisms (63.1%).
Conclusion: Ceftazidime plus amikacin is not effective as
an initial empirical therapy for adult patients with febrile
neutropenia.
Table 2. Causative microorganisms isolated from 19 febrile episodes
Microorganism No. of
isolates
Ceftazidime
sensitive
Amikacin
sensitive
Escherichia coli 3 1/3 3/3
Staphylococcus aureus 2 1/3 2/3
Pseudomonas aeruginosa 3 2/3 3/3
Klebsiella pneumoniae 1 1/1 1/1
Enterobacter spp. 2 1/2 2/2
Bacillus 1 1/1 1/1
Streptococcus pneumoniae 2 1/2 1/2
Enterococcus faecalis 1 1/1 1/1
MRSE 1 n/a n/a
Acinetobacter spp. 1 1/1 1/1
Moraxella 2 2/2 2/2
NA: not available; MRSE: methicillin-resistant Staphylococcus epider-
midis.
PP-010 Effect of three Nigerian medicinal plants on
methicillin resistant Staphylococcus aureus
(MRSA)
O. Omonike1,2 *, W. Mutiu2. 1University of Ibadan, Ibadan,
2Olabisi Onabanjo University, Sagamu, Nigeria
Background: Over the last decades, methicillin resistant
Staphylococcus aureus (MRSA) had caused major problems
in the hospitals throughout the world. Cajanus cajan,
Kigelia africana, Plumbago zeylanica are medicinal plants
commonly prescribe by traditional medical practitioner in
Nigeria for treatment of infectious diseases, they were
tested in vitro for their anti-MRSA properties against ﬁve
clinical isolate of MRSA. The bacterial cultures used were
strains isolated from patients.
Objectives: The objective of the study is to conﬁrm the
activity of these medicinal as claimed by the traditional
medical practitioner.
Methods: Fresh plant materials were collected and air
dried; methanol extracts of the powdered plants samples
were obtained by standard methods. Diameter zone of
inhibition was used as a measure of the anti-MRSA properties
using Gentamicin and Oﬂoxacin as reference standard in
Agar diffusion assay.
Results: The result revealed that the crude extracts of the
leaf of Cajanus cajan and the root of Plumbago zeylanica
were effective against MRSA with MIC as low as 3.98mg/ml
and 1.58mg/ml respectively while the methanol extract of
the bark of Kigelia africana showed no signiﬁcant activity
against MRSA. Partitioning of the two active plant extracts
into solvents of varying degree of polarity indicates that,
the activities of the two plants lies more in their polar and
moderately polar constituent.
Conclusion: The result of this study offers a scientiﬁc basis
for the use of the extracts of Cajanus cajan and Plumbago
zeylanica against MRSA associated diseases.
